Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets and other non-current assets of $715K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets increased by 16.1% year-over-year, from $616K to $715K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets has grown at a -20.4% compound annual growth rate (CAGR), from $389K to $124K.